甲状腺激素与非酒精性脂肪性肝病研究进展*

doi:10.3969/j.issn.1672-5069.2023.01.038

Abstract

Abstract: The nonalcoholic fatty liver disease (NAFLD) is considered to be the metabolic disorders in liver and is closely related to obesity, insulin resistance (IR), type 2 diabetes mellitus (T2DM) and hyperlipemia, etc. The prevalence of NAFLD among adults worldwide is about 25% and it is to believe increasing year by year. The NAFLD is an important causes of liver cirrhosis, liver cancer and liver transplantation. A large number of studies have shown that thyroid hormone (THs) plays an important role in hepatic lipid metabolism and IR, and the thyroid hormone receptor agonists are expected to become new medicines for the treatment of patients with NAFLD. In this review, we mainly discuss the progress of THs in patients with NAFLD.

Key words: Nonalcoholic fatty liver disease, Metabolic-associated fatty liver diseases, Thyroid hormone

Chen Yi,Zhu You,Zhou Xiqiao. Serum thyroid hormone levels in patients with nonalcoholic fatty liver disease[J]. Journal of Practical Hepatology, 2023, 26(1): 145-148.

References

[1] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018,67(1):328-357.
[2] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年版).实用肝脏病杂志,2018,21(2):177-186.
[3] Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med (Lond), 2018,18(3):245-250.
[4] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016,64(1):73-84.
[5] Eslam M, Sanyal AJ, George J. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 2020,158(7): 1999-2014,e1.
[6] Kim D, Kim W, Joo SK, et al. Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis. Clin Gastroenterol Hepatol, 2018,16(1):123-131,e1.
[7] He W, An X, Li L, et al. Relationship between hypothyroidism and non-alcoholic fatty liver disease: A systematic review and Meta-analysis. Front Endocrinol (Lausanne), 2017,8:335.
[8] Pagadala MR, Zein CO, Dasarathy S, et al. Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci, 2012,57(2):528-534.
[9] Eshraghian A, Hamidian Jahromi A. Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review. World J Gastroenterol, 2014,20(25): 8102-8109.
[10] Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev, 2001,81(3):1097-1142.
[11] Fonseca TL, Fernandes GW, McAninch EA, et al. Perinatal deiodinase 2 expression in hepatocytes defines epigenetic susceptibility to liver steatosis and obesity. Proc Natl Acad Sci U S A, 2015,112(45):14018-14023.
[12] Fonseca TL, Fernandes GW, McAninch EA, et al. Perinatal deiodinase 2 expression in hepatocytes defines epigenetic susceptibility to liver steatosis and obesity. Proc Natl Acad Sci U S A, 2015,112(45):14018-14023.
[13] Gionfra F, De Vito P, Pallottini V, et al. The role of thyroid hormones in hepatocyte proliferation and liver cancer. Front Endocrinol (Lausanne), 2019,10:532.
[14] Sinha RA, Bruinstroop E, Singh BK, et al. Nonalcoholic fatty liver disease and hypercholesterolemia: Roles of thyroid hormones, metabolites, and agonists. Thyroid, 2019,29(9):1173-1191.
[15] Baumann CT, Maruvada P, Hager GL, et al. Nuclear cytoplasmic shuttling by thyroid hormone receptors. multiple protein interactions are required for nuclear retention. J Biol Chem,2001,276(14):11237-11245.
[16] Hönes GS, Rakov H, Logan J, et al. Noncanonical thyroid hormone signaling mediates cardiometabolic effects in vivo. Proc Natl Acad Sci U S A, 2017,114(52):E11323-E11332.
[17] Jornayvaz FR, Lee HY, Jurczak MJ, et al. Thyroid hormone receptor-α gene knockout mice are protected from diet-induced hepatic insulin resistance. Endocrinology, 2012,153(2):583-591.
[18] Araki O, Ying H, Zhu XG, et al. Distinct dysregulation of lipid metabolism by unliganded thyroid hormone receptor isoforms. Mol Endocrinol, 2009, 23(3):308-315.
[19] Krause C, Grohs M, El Gammal AT, et al. Reduced expression of thyroid hormone receptor βin human nonalcoholic steatohepatitis. Endocr Connect, 2018, 7(12):1448-1456.
[20] Mashek DG. Hepatic fatty acid trafficking: multiple forks in the road. Adv Nutr, 2013,4(6):697-710.
[21] Feng X, Jiang Y, Meltzer P, et al.Thyroid hormone regulation of hepatic genes in vivo detected by complementary DNA microarray. Mol Endocrinol, 2000, 14(7):947-955.
[22] Wang Y, Viscarra J, Kim SJ, et al. Transcriptional regulation of hepatic lipogenesis. Nat Rev Mol Cell Biol, 2015,16(11):678-689.
[23] Grasselli E, Voci A, Demori I, et al. Triglyceride mobilization from lipid droplets sustains the anti-steatotic action of iodothyronines in cultured rat hepatocytes. Front Physiol, 2016,6:418.
[24] Simó R, Hernández C, Sáez-López C, et al. Thyroid hormone upregulates zinc-α2-glycoprotein production in the liver but not in adipose tissue. PLoS One, 2014,9(1):e85753.
[25] Sinha RA, You SH, Zhou J, et al. Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy. J Clin Invest, 2012,122(7):2428-2438.
[26] Sinha RA, Singh BK, Yen PM. Direct effects of thyroid hormones on hepatic lipid metabolism. Nat Rev Endocrinol,2018,14(5):259-269.
[27] Ness GC, Pendleton LC, Li YC, et al. Effect of thyroid hormone on hepatic cholesterol 7 alpha hydroxylase, LDL receptor, HMG-CoA reductase, farnesyl pyrophosphate synthetase and apolipoprotein A-I mRNA levels in hypophysectomized rats. Biochem Biophys Res Commun,1990,172(3):1150-1156.
[28] Lopez D, Abisambra Socarrás JF, Bedi M, et al. Activation of the hepatic LDL receptor promoter by thyroid hormone. Biochim Biophys Acta, 2007, 1771(9):1216-1225.
[29] Iannucci LF, Cioffi F, Senese R, et al. Metabolomic analysis shows differential hepatic effects of T2 and T3 in rats after short-term feeding with high fat diet.Sci Rep, 2017,7(1):2023.
[30] Chi HC, Tsai CY, Tsai MM, et al. Molecular functions and clinical impact of thyroid hormone-triggered autophagy in liver-related diseases. J Biomed Sci, 2019,26(1):24.
[31] Bonde Y, Breuer O, Lütjohann D, et al. Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans. J Lipid Res, 2014,55(11):2408-2415.
[32] Zhang X, Song Y, Feng M, et al. Thyroid-stimulating hormone decreases HMG-CoA reductase phosphorylation via AMP-activated protein kinase in the liver. J Lipid Res, 2015,56(5):963-971.
[33] Song Y, Xu C, Shao S, et al. Thyroid-stimulating hormone regulates hepatic bile acid homeostasis via SREBP-2/HNF-4α/CYP7A1 axis. J Hepatol, 2015, 62(5): 1171-1179.

Serum thyroid hormone levels in patients with nonalcoholic fatty liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Chen Fenglian, Zhu Qinglan, Zhu Lingli, et al. Different activation of peripheral blood invariant natural killer T cells and CD4⁺/CD8⁺T cells in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(1): 31-34.
[2]	Li Xiangyang, Ding Guangwei, Jin Ming. Efficacy of entecavir in treatment of patients with chronic hepatitis B and non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(6): 776-779.
[3]	Wang Xiaohua, Zeng Yalin, Guo Cuirong. Impact of impaired fasting glucose and insulin resistance on liver fibrosis in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(6): 812-815.
[4]	Liu Yantong, Yao Yang, Lu Bo. Short-term efficacy of Heye Tiaozhi Shugan Decoction in dealing with patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(5): 657-660.
[5]	Pan Fei, Shou Juan, Zhang Dongqing. Short-term efficacy of different statins in treatment of patients with nonalcoholic fatty liver disease and hyperlipidaemia [J]. Journal of Practical Hepatology, 2022, 25(5): 665-668.
[6]	Wang Hui, Tang Zhan, Chang Wenjuan, et al.. Comparison of metabolic characteristics and liver steatosis in non-obese and obese patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(5): 669-672.
[7]	CheDepartment of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai , Chinan Mengqi, Fan Jiangao. Brief introduction of a clinical practice guideline for the diagnosis and management of patients with nonalcoholic fatty liver diseases in USA [J]. Journal of Practical Hepatology, 2022, 25(5): 0-S16.
[8]	Wang Qing, Zhang Lili. When T2DM comes across with NAFLD:1+1＞2？ [J]. Journal of Practical Hepatology, 2022, 25(4): 460-463.
[9]	Zhang Wenyan, Liu Fang, Liu Menglu, et al. Plasma exosome differential proteins in patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(4): 521-525.
[10]	Cai Dongmei, Wu Wenjuan, Jiang Yilun, et al. Implication of hepatic fat fraction by CT angiography in patients with nonalcoholic fatty liver diseases and high-risk coronary plaque [J]. Journal of Practical Hepatology, 2022, 25(3): 383-386.
[11]	Zhou Ping, Yao Dengfu, Yao Min. Hepatocyte malignant transformation in circumstances of nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(2): 157-160.
[12]	Chen Kai, Ju Feng. Observation of hepatic steatosis score by ultrasonography in patients with nonalcoholic fatty liver diseases after polyene phosphatidylcholineand Fuzheng Huayu capsule combination treatment [J]. Journal of Practical Hepatology, 2022, 25(2): 219-222.
[13]	Li Wei, Huang Yu, Zhong Jing, et al. Correlation of PNPLA3 rs738409 gene polymorphism to genetic susceptibility of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2022, 25(2): 227-230.
[14]	Zhou Xiaoyong, Bai Yangqiu, Yang Hui, et al. Changes of serum thyroid hormone levels andprevalence of anti-thyroid antibodies in patients with primary biliary cholangitis [J]. Journal of Practical Hepatology, 2022, 25(1): 46-49.
[15]	Lyu Chunhui, Li Dawei, Wang Xiaojie, et al. Short-term impact of metformin an simvastatin combination therapy on blood glucose and lipid parameters in patients with nonalcoholic fatty liver disease with concomitant diabetes mellitus type 2 [J]. Journal of Practical Hepatology, 2022, 25(1): 50-53.